Integrated analysis of ethionamide resistance loci in Mycobacterium tuberculosis clinical isolates

Tuberculosis patients taking second line drugs such as ethionamide (ETH) have often experienced previous treatment failure and usually have a complex history of disease and treatment that can span decades. Mutations in the ETH activating enzyme, EthA, confer resistance through undescribed mechanisms. To explore the impact of EthA mutations on ETH resistance, data from a total of 160 ETHR isolates was analysed. The most frequently mutated positions are within regions that display sequence conservation with the active site of OTEMO, another FAD-containing NADH-binding Baeyer-Villiger monooxygenase (BVMO), or with the sugar binding site of galectin-4.

Source: Tuberculosis - August 26, 2018 Category: Respiratory Medicine Authors: Duanne Alves da Silva, Nicole Victor Ferreira, Amanda Mendes Rego, Pamela Chrystina Pinto Barbosa, Rodrigo Fernandes Machado, Alessandra Pimentel, Lusiano Motta dos Reis, Lucindo Cardoso de Pina, Paulo Redner, Paulo Cesar de Souza Caldas, F átima Cristin Tags: Drug Discovery and Resistance Source Type: research